Qiagen (QGEN) Set to Announce Earnings on Monday

Qiagen (NYSE:QGEN) will be posting its quarterly earnings results after the market closes on Monday, April 29th. Analysts expect Qiagen to post earnings of $0.44 per share for the quarter. Qiagen has set its FY 2024 guidance at 2.100- EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.55 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.55. Qiagen had a net margin of 17.37% and a return on equity of 12.99%. The company had revenue of $509.00 million during the quarter, compared to analysts’ expectations of $500.77 million. During the same quarter in the prior year, the company posted $0.53 EPS. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Up 1.4 %

QGEN opened at $41.65 on Friday. The firm’s 50-day simple moving average is $42.58 and its 200-day simple moving average is $42.66. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.62 and a current ratio of 1.99. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.70. The firm has a market cap of $9.50 billion, a price-to-earnings ratio of 27.53, a PEG ratio of 3.47 and a beta of 0.41.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Morgan Stanley raised shares of Qiagen from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup decreased their price objective on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.69.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.